Linder the Panerunik Reduction Act of 1995, no negative are received to

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10647068
Filing Date		2003-08-22
First Named Inventor Arger		ita, et al.
Art Unit		3733
Examiner Name PHIL		OGENE, PEDRO
Attorney Docket Number		0101-2977US1

					U.S.I	PATENTS			Remove	
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue E)ate	Name of Pate of cited Docu	entee or Applicant ment	Releva	Columns,Lines when int Passages or Rele s Appear	
	1									
If you wish	h to a	dd additional U.S. Pate	nt citatio	n inform	ation pl	ease click the	Add button.		Add	
			U.S.P	ATENT	APPLI	CATION PUBL	LICATIONS		Remove	
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publica Date	tion	Name of Pate of cited Docu	entee or Applicant ment	Releva	Columns,Lines when int Passages or Rele s Appear	
	1									
If you wish	h to a	dd additional U.S. Publi						d button		
	_			FOREIG	SN PAT	ENT DOCUM	ENTS		Remove	_
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ²		Kind Code ⁴	Publication Date	Name of Patente Applicant of cited Document	e or	Pages,Columns,Line where Relevant Passages or Relevar Figures Appear	T.
	1									_
If you wish	h to a	dd additional Foreign P	atent Do	cument	citation	information pl	ease click the Add	button	Add	
			NON	I-PATE	NT LITE	RATURE DO	CUMENTS		Remove	
Examiner Cite Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.					Τs					

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10647068	
Filing Date		2003-08-22	
First Named Inventor	Argenta, et al.		
Art Unit		3733	
Examiner Name PHILO		OGENE, PEDRO	
Attorney Docket Number		0101-2977US1	

1	PARIKH, R.S., et al., "Self-adhesive drape (Opsite) for management of leaking abdominal wounds", Indian J. Gastroenterol., 19(4):178-180 (October / December 2000). NPL-631	
2	MILLER, S.J., "Surgical wound drainage system using silicone tubing", J. Am. Podiatry Assn., 71(6); pp. 287-296 (June 1981). NPL-605	
3	ALEXIS, A.F., et al., "Reassessment of the suction blister model of wound healing: introduction of a new higher pressure device", Int. J. Dermatot, 38(8):613-617 (August 1999). NPL-632	
4	GNANARAJ, J., "A simple, sterile, low-cost, closed suction dramage system", Trop. Doct., 27(2):104 (April 1997). NPL-633	
5	KLEMM, K.W., "Antibiotic bead chains", Clin. Orthop. Rel. Res., (295):63-76 (October 1993). NPL-834	
6	PIGNATTI, M., et al., "Mobile-VAC for the treatment of lower limb ulcers", Plast. Reconstr. Surg., 108(6):1837-1838 (November 2001). NPL-835	
7	SCHAUM, K.D., "Payment strategies: a new medicare part B wound care policy", Adv. Skin & Wound Care, 14 (5):238-240 (September / October 2001). NPL-636	
8	CHARIKER, M.E., Presentation entitled, "Vacuum therapy in wound management", (Chariker deposition exhibit no. 1220), dated October 27, 2005. NPL-637	
9	CHARIKER, M.E., Presentation entitled, "Closed wound suction", (Chariker deposition exhibit no 1219), dated March 17, 2005. NPL-638	
10	Opposition to EP 0,620,720 - Letter to European Patent Office regarding Paul Hartmann AG, (7 sheets) (dated March 6, 2006). EPOPWH1-27	
11	NELSON, R.P., et al., "Use of negative pressure sudion in urology", Urology, 4(5):574-576, (November 1974). NPL-494	

12	FEIERABEND, T.C., et al., "Injuries causing major loss of scalp", Plast, Reconstr. Surg., [Abstract only - 1 pp. printout from PubMed], 76(2):189-194 (August 1985). NPL-623	

If you wish to add additional non-patent literature document citation information please click the Add button Add

EXAMINER SIGNATURE

Examiner Signature Date Considered Date Considered

Date Considered

Examiner Signature

Date Considered

Da

1 See Kind Codes of USPTO Patent Documents at steer_USETO_GOV or MPEP 991.04. ² Enter office that issued the document, by the two-letter code (WPDO Standard ST, 3). ³ For Japonese patent documents, the obtained or the year of the rispon of the Emperor must precede the serial number of the patent document. ³ Mind of document of the year operations and collection of the document under VPD Standard ST, 40 Septions, ³ Applicated is to size as of extent more continued on the patent document under VPD Standard ST, 40 Septions, ³ Applicated is to size as of extent more continued to the patent document under VPD Standard ST, 40 Septions, ³ Applicated is to size as of extent more continued to the patent document under VPD Standard ST, 40 Septions, ³ Applicated is to size as of extent more continued to the patent of the patent document under VPD Standard ST, 40 Septions, ³ Applicated is not size as of extent more continued to the patent document of the patent document under VPD Standard ST, 40 Septions, ³ Applicated is not size as of extent more continued to the patent document under VPD Standard ST, 40 Septions, ³ Applicated is not size as of extent more continued to the patent document under VPD Standard ST, 40 Septions, ³ Applicated ST, 40 Septions, ³ Applicated ST, 40 Septions ST, 40 Septions, ³ Applicated ST, 40 Septions, ³ Applicated ST, 40 Septions, ³ Applicated ST, 40 Septions ST, 40 Septions, ³ Applicated ST, 40

English language translation is attached.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 GFR 1.99)

Application Number		10647068	
Filing Date		2003-08-22	
First Named Inventor	Argenta, et al.		
Art Unit		3733	
Examiner Name	PHILO	OGENE, PEDRO	
Attorney Docket Number		0101-2977US1	

CERTIFICATION STATEMENT

Please see 37	CFR 1.97	and 1.98 to	make the appro	priate selection(s	s):
---------------	----------	-------------	----------------	--------------------	-----

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filling of the information disclosure statement. See 37 CFR 1.97(e/11).

OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any involved designated in 37 CFR 1.56(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(s).

- See attached certification statement.
- Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/Niels Haurr/	Date (YYYY-MM-DD)	2007-04-18
Name/Print	Niels Haun	Registration Number	48 488

This collection of information is required by 3T CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is for life railed by the USPTO to process) an application. Confidentiality is governed by \$5 U.S. C. 12.0 and 3T CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete his form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Tradenary Cfing. U.S. Operatment of Commence, P. 0. Box 1450, Alexandria, V.S. 2313-1450. D. ONT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, V.S. 2313-1450.

Privacy Act Statement

The Privacy Act of 1974 (P. L. 93-579) requires that you be given certain information in connection with your submission of the stackhold from related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, places be advised that (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) familishing of the information solicided is couldrain; and (3) the primoral pursuance for which the information is used by the U.S. Patient and Trademan Coffice is to process and/or examine your submission related to a patient agricultant or patient. If you do not furnish the requested process and/or examine your submission related to a patient agricultant or patient. If you do not furnish the requested results of the patient of the patient and the patient of the patient

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
 - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiation.
 - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
 - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552(m).
 - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
 may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
 to the Patent Cooperation Treaty.
 - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
 - 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designed, uturing an insection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 4d U.S.C. 2904 and 2905. Such disclosure shall be made in accordance with the GSA requisions governing inseption of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the
 application pursuant to 35 U.S.C. 12(2) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be
 disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filled in application
 which became abandoned or in which the proceedings were terminated and which application is referenced by either a
 published application, an application open to public inspections or as issued patent.
 - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.